CD274 and nonpapillary renal cell carcinoma: Evidence suggests that genomic indicators, which show a correlation with ICB efficacy in other solid tumours—like tumour mutational burden (TMB) and PD‐L1 expression levels [15, 16, 17], fail to forecast therapeutic success in ccRCC [18, 19].